Study highlights previously untapped potential of genetically engineered macrophages in immunotherapy for solid tumors.
Carisma Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the company will present at two conferences in March, 2020.
Carisma Therapeutics expands leadership with appointments of Debora Barton, MD as Chief Medical Officer, and Tom Wilton as Chief Business Officer.
Carisma Therapeutics Senior Scientist Konrad Gabrusiewicz, PhD, will present an abstract titled "CT-0508, a novel CAR macrophage product directed against HER2, promotes a pro-inflammatory tumor microenvironment" at the AACR Tumor Immunology and Immunotherapy 2019 meeting taking place November 17-20 in Boston, MA.
Carisma Therapeutics announced today that it will be participating in three upcoming investor conferences.
Carisma's VP of Business Development, Dora Mitchell, PhD and VP of Discovery Research, Michael Klichinsky, PharmD, PhD chaired and presented at the inaugural macrophage-directed therapies summit taking place October 22-24, 2019 in Boston, MA.